Rituximab Offlabel denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Rituximab Claim as Duplicate Therapy

A duplicate-therapy denial means BCBS has determined that rituximab overlaps with another biologic or immunosuppressive agent already on your active medication list. This is common with rituximab used off-label, because BCBS coverage policies typically require that a patient not be receiving two agents targeting the same pathway or serving the same clinical function simultaneously.

This denial is worth appealing. Rituximab's mechanism of action — B-cell depletion via CD20 targeting — is distinct from most conventional immunosuppressants and from many other biologics. Your prescriber can document exactly why combination or sequential use is clinically indicated for your specific diagnosis and why it does not represent true therapeutic duplication.

## Your Federal Appeal Rights

• Internal appeal: You have the right to a full-and-fair internal review under ERISA §503 (job-based plans) or your plan's grievance process. Submit within the timeframe stated on your denial letter, typically 180 days.
• External review: Under ACA §2719, if the internal appeal fails you may request an Independent Review Organization (IRO) review. You generally have four months from the final internal denial to file.
• Expedited option: If your condition is urgent, request expedited internal and external review simultaneously — decisions are typically required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — chart notes, specialist letters, and any pathology or lab reports establishing your diagnosis. 2. Current medication list — a complete reconciled list showing every active agent, its indication, and its mechanism of action. 3. Prescriber medical-necessity letter — your physician should explicitly explain why rituximab is not duplicative, citing the distinct mechanism and the clinical rationale for the current regimen. 4. Relevant guideline support — ask your prescriber to reference the applicable guideline organization (e.g., ACR, ASH, or the relevant specialty society) supporting this combination or sequencing strategy. 5. Treatment history — prior therapies tried, dates started and stopped, and documented reasons for discontinuation or inadequate response.

## Criteria-Mapping Structure

Obtain a copy of BCBS's current published coverage/medical policy for rituximab and your specific condition. For each requirement the policy lists, prepare a one-sentence answer citing the exact page and date of the corresponding chart record. Your prescriber's letter should walk through every criterion in the same order the policy presents them, addressing the duplicate-therapy exclusion directly with mechanism-of-action evidence.